$PTHS News
Last published 1w ago
- 1w agoPTHSPelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireDURHAM, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs
- 1w agoPTHSPelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the SkinGlobeNewswireStrategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary
- 2w agoALTPTHSAltimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic EvolutionGlobeNewswireBoard appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M.
- 3mo agoPTHSPelthos Therapeutics Announces Second Quarter 2026 Financial ResultsGlobeNewswireZelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the
- 3mo agoPTHSPelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026GlobeNewswireDURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs
- 4mo agoPTHSPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark IndexesGlobeNewswireDURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs,
- 4mo agoPVLASVRASLNOSBBP+2Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsGlobeNewswireBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease
- 5mo agoPTHSPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare ConferenceGlobeNewswireDURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today
- 6mo agoPTHSPelthos Therapeutics Announces First Quarter 2026 Financial ResultsGlobeNewswireZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique
- 6mo agoPTHSPelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026GlobeNewswireDURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today
- 7mo agoPTHSPelthos Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumGlobeNewswireDURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"),
- 7mo agoPTHSPelthos Therapeutics Announces CFO TransitionGlobeNewswireDURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"),
- 7mo agoPTHSPelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye PainGlobeNewswireFirst clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of
- 8mo agoPTHSPelthos Therapeutics to Present at 38th Annual ROTH ConferenceGlobeNewswireDURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"),
- 8mo agoPTHSPelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026GlobeNewswireDURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"),
- 8mo agoPTHSPelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireDURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today
- 10mo agoHRZNPTHSHorizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos TherapeuticsBusiness WireHorizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc.
- 10mo agoHRZNPTHSPelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology FinanceGlobeNewswireDURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today
- 10mo agoPTHSPelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head LiceGlobeNewswireAcquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age
- 10mo agoPTHSPelthos Therapeutics Expands Board of Directors with the Appointment of Andrew EinhornGlobeNewswireDURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today
- 11mo agoPTHSPelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%GlobeNewswireZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported
- 11mo agoPTHSPelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireDURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today
- 12mo agoPTHSPelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial ResultsGlobeNewswireConference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net
- 1y agoLGNDPTHSPelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes FinancingGlobeNewswireAcquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in
- 1y agoPTHSPelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025GlobeNewswireDURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), will
- 1y agoPTHSPelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum ContagiosumGlobeNewswireThe Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversationMolluscum is a highly contagious skin infection affecting
- 1y agoPTHSPelthos Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireDURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high
- 1y agoPTHSPelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare ConferenceGlobeNewswireDURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high
- 1y agoPTHSPelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business UpdateGlobeNewswireFiles Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer)
- 1y agoCHROPTHSPelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum ContagiosumGlobeNewswireZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by
- 1y agoLGNDPTHSLigand Partner Pelthos Therapeutics Launches ZELSUVMI™GlobeNewswireJUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has commercially launched ZELSUVMI™